



Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

November 23, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 23, 2021-- Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern Time.

A webcast of the event will be accessible on the [Investor Calendar](#) page under the News & Events heading of Cortexyme's investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Cortexyme's lead program targets a specific, infectious pathogen called *P. gingivalis* found in the brain of Alzheimer's patients and other organs and tied to degeneration and inflammation in humans and animal models. The company's causation evidence for Alzheimer's disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20211123005528/en/>

Stacy Roughan
Vice President, Corporate Communications & Investor Relations
Cortexyme, Inc.
ir@cortexyme.com

Source: Cortexyme, Inc.